SCHEMBL6476329

SCHEMBL6476329

O=C(O)C(=Cc1ccc(OCCn2c(=O)sc3cc(NC(=O)c4ccccc4)ccc32)cc1)C(=O)O

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 6/20 0.50
TP53 P04637 5/20 0.50
PPARG P37231 5/20 0.50
NPC1 O15118 4/20 0.47
RAB9A P51151 4/20 0.47
SMN1; SMN2 Q16637 4/20 0.47
ALDH1A1 P00352 1/20 0.47
TSHR P16473 1/20 0.47
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 2/20 0.45
LMNA P02545 2/20 0.45
PPARA Q07869 8/20 0.44
CYP1A2 P05177 1/20 0.42
CYP3A4 P08684 1/20 0.42
CYP2D6 P10635 1/20 0.42
CYP2C9 P11712 1/20 0.42
CYP2C19 P33261 1/20 0.42
KDM4E B2RXH2 1/20 0.42
POLB P06746 1/20 0.42
HPGD P15428 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6475893 0.91 PPARG (0.52) MAPTTP53PPARGNPC1RAB9A
SCHEMBL6477169 0.85 PPARG (0.64) TP53PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL6476836 0.83 PPARA (0.56) TP53PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL6476834 0.83 PPARA (0.56) TP53PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL6489058 0.83 PPARG (0.66) MAPTTP53PPARGNPC1RAB9A
SCHEMBL6487303 0.83 RAB9A (0.70) MAPTTP53PPARGNPC1RAB9A
SCHEMBL6531209 0.81 PPARG (0.59) TP53PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL5913753 0.81 PPARG (0.61) TP53PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL6476460 0.81 PPARG (0.57) TP53PPARGNPC1RAB9ASMN1; SMN2
SCHEMBL5913749 0.81 PPARG (0.61) TP53PPARGNPC1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6919362-B2 Heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2005-07-19 US disclosed
EP-1252150-B1 HETEROCYCLIC DERIVATIVES, PREPARATION METHOD AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME SERVIER LAB (FR) 2003-06-04 EP disclosed
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same LES LABORATOIRES SERVIER (FR) 2003-02-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030040533-A1 Novel heterocyclic derivatives, preparation method and pharmaceutical compositions containing same CYP2F1, CYP11B2, CYP4B1 MAPT 3539/4885TP53 3596/4885PPARG 414/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.